文献速递肝病消化道肿瘤与早癌

CD48:肝细胞癌肿瘤相关巨噬细胞的新型免疫检查点

CD48 is a novel immune checkpoint on tumour-associated macrophages in hepatocellular carcinoma.
PubMed 文献 · Gut · 2026-01-02

该研究通过多组学分析发现CD48+肿瘤相关巨噬细胞与肝细胞癌进展、免疫治疗耐药及不良预后相关。机制上CD48与MMP14顺式互作激活RAP1-YAP-STAT3通路上调免疫抑制基因,靶向CD48可抑制肿瘤并与抗PD1协同。

要点

  • CD48+ TAM与HCC进展、免疫治疗耐药及不良预后相关
  • CD48通过MMP14-RAP1-YAP-STAT3轴促进免疫抑制
  • 抗CD48单药及联合抗PD1在HCC模型中显示疗效

核心结论

  • CD48是TAM上驱动HCC进展和免疫治疗耐药的新型免疫检查点,靶向CD48可克服免疫抑制并提高疗效。

研究设计与样本

  • 对HCC临床标本进行整合多组学分析并在独立队列中验证,单细胞RNA测序鉴定TAM亚群。
  • 功能表征采用全身及巨噬细胞特异性CD48敲除小鼠、过继转移实验和共培养系统。
  • 机制研究使用免疫沉淀-质谱、免疫荧光共定位和通路分析。
  • 疗效评估在原位HCC模型中使用抗CD48单药及联合抗PD1治疗。

主要发现

  • CD48+ TAM与加速的肿瘤进展、免疫治疗耐药和不良临床结局相关。
  • CD48+ TAM表现促肿瘤表型,驱动免疫抑制并促进细胞外基质重塑。
  • 遗传性CD48敲除减缓HCC进展并促进CD8+ T细胞功能。
  • 过继转移CD48缺陷巨噬细胞验证了肿瘤抑制效应。
  • MMP14被鉴定为CD48的新型顺式互作伙伴,不依赖经典CD48-CD244轴;该互作激活RAP1 GTP酶,触发YAP核转位及YAP-STAT3复合物形成以上调免疫抑制基因。

临床怎么用

  • CD48+ TAM可作为HCC免疫治疗耐药的潜在生物标志物和治疗靶点。
  • 抗CD48抗体单药或联合抗PD1可能成为HCC的治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality with limited therapeutic options. Despite promising immunotherapy, response rates remain suboptimal. Tumour-associated macrophages (TAMs) constitute a pivotal component of the immunosuppressive HCC microenvironment, yet TAM heterogeneity and contributions to tumour progression and immunotherapy resistance remain poorly defined. OBJECTIVE: To identify and characterise critical TAM subsets in HCC and evaluate their potential as therapeutic targets. DESIGN: Integrated multiomics analysis of hepatocellular carcinoma (HCC) clinical specimens was performed and validated across independent cohorts. Single-cell RNA sequencing identified tumour-associated macrophage (TAM) subpopulations. Functional characterisation employed whole-body and macrophage-specific CD48 knockout mice, adoptive transfer experiments and co-culture systems. Mechanistic studies used immunoprecipitation-mass spectrometry, immunofluorescence colocalisation and pathway analysis. Therapeutic efficacy was evaluated using anti-CD48 monotherapy and combination with anti-programmed cell death protein 1 (PD1) in orthotopic HCC models. RESULTS: CD48+ TAMs were identified associating with accelerated tumour progression, immunotherapy resistance and poor clinical outcomes. These TAMs exhibited protumorous phenotypes, driving immunosuppression and promoting extracellular matrix remodelling. Genetic CD48 ablation attenuated HCC progression while promoting CD8+ T-cell function. Adoptive transfer of CD48-deficient macrophages validated tumour-suppressive effects. Mechanistically, matrix metalloproteinase-14 (MMP14) was identified as a novel cis-interacting partner for CD48, functioning independently of the canonical CD48-CD244 axis. This interaction activated RAP1 GTPase, triggering Yes-associated protein (YAP) nuclear translocation and YAP-signal transducer and activator of transcription 3 (STAT3) complex formation to upregulate immunosuppressive genes. Anti-CD48 antibodies effectively inhibited tumour progression and demonstrated synergistic effects with anti-PD1 therapy. CONCLUSION: CD48 represents a novel immune checkpoint on TAMs critical for HCC progression and immunotherapy resistance. Targeting CD48 may overcome immunosuppression and increase therapeutic efficacy in HCC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Shi G, Xiao Y, Li Z, et al. CD48 is a novel immune checkpoint on tumour-associated macrophages in hepatocellular carcinoma. Gut. 2026. PMID: 41482455. doi:10.1136/gutjnl-2025-336744

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。